Does THC content tell you everything about the effect?

THC was the first active compound that could be measured in a standardised way, and prices were tied to it. "Higher percentage, harder high" is the intuitive expectation. In the pharmacy as in cannabis marketing, THC sits right at the top of the label. That builds a strong link between the number and the effect, one that simply does not hold up.

The most rigorous study on the question so far comes from Bidwell, Hutchison et al. 2020 in JAMA Psychiatry¹. 121 adult cannabis users were observed in a natural setting, with blood THC and subjective intoxication measured before, right after and one hour after use. One group used legally bought flower (16–24% THC), the other concentrates (70–90% THC).

The result is one of the central findings in modern cannabis research: concentrates pushed the THC blood level to 1,016 ng/ml and flower to 455 ng/ml, yet the reported intoxication and the cognitive impairment were identical.

Lead author Cinnamon Bidwell summed it up: "Potency does not correlate with intoxication. We saw drastic differences in blood level, but the effect was comparable." So a higher percentage does not necessarily get you "higher".

A follow-up study from the same group (Bidwell et al. 2021, Scientific Reports²) compared THC-dominant and CBD-dominant concentrates. The positive subjective effects (drug liking, feeling good) were similar in both groups. What differed: paranoia and anxiety spiked sharply right after use in the THC group, while the CBD group showed lower tension and anxiety scores from the start.

That is a very direct observation of the CBD modulation effect: same THC, add CBD, and the subjective picture flips from "tense-paranoid-high" to "relaxed-high". A strain with 22% THC and 0% CBD behaves differently from one with 22% THC and 4% CBD. The number on the label stays the same.

A later exploratory analysis (Hutchison et al. 2023³) also showed that the baseline state, anxiety level and depressive symptoms at the moment of use modulate the acute effect. Reaching for a strain while tense gives you a different experience than reaching for the same strain while relaxed.

Regular use builds tolerance. Ramaekers et al. 2016 in Scientific Reports⁴ showed in heavy users that at comparable THC blood levels the subjective and cognitive effects were markedly blunted. The mechanism is a downregulation of CB1 receptors: the cannabinoid system adapts.

The consequence: in a patient who uses daily, a 25% strain produces a different effect than it does in a naive first-time user. THC content explains nothing without the context of use. An honest strain recommendation has to account for tolerance.

Follow the THC number and you may well be following a wrong number. Schwabe et al. 2023 (PLoS ONE⁵, "Uncomfortably high") tested commercial cannabis labels and found a systematic overstatement of THC values against lab measurements. A 2025 study in Scientific Reports⁶ confirmed this broadly: only 56.7% of flower products fell within ±15% of the stated THC concentration. For concentrates it was 96%. So with flower, nearly every second product deviates substantially from its label.

For patients that means: if the starting figure is already unreliable, reading the effect off the label is doubly uncertain.

The effect of a cannabis flower is the interplay of several variables, and THC is only one of them:

1. Terpene profile. A 22% strain weighted toward myrcene/linalool feels physically sedating; the same THC strength weighted toward limonene/α-pinene feels clear and activating. Russo 2011⁷ laid the theoretical groundwork, and newer work (see the myth One terpene = one effect) refines the picture.

2. CBD and minor cannabinoid content. CBD modulates the THC effect (Bidwell 2021). CBG, CBN and THCV each have their own profile.

3. Consumption method. Inhaled, it hits fast and shorter; taken orally, it sets in later and lasts longer. Same dose, different window of effect.

4. Tolerance and setting. Use history, time of day, mood, expectation. All documented modulators.

The serious way to assess a strain is therefore the chemovar (see the myth Indica vs. Sativa dogma): the full chemical profile. Smith et al. 2022⁸ showed that even strains sharing a name vary widely in THC and terpenes between producers, so the strain name is no shortcut either.

THC is the dosing, the terpene profile is the character. Picking by THC percentage alone at the pharmacy throws away information that is often right there on the label: for Bedrocan, Tilray or Aurora import stock, terpene profiles are documented in the certificates of analysis.

Three pragmatic steps:

1. Ask your pharmacist explicitly for the certificate of analysis (CoA); that is where the terpene profile sits.

2. Note your own reactions: which terpene was dominant, what was the effect, in what setting? The database builds up personally.

3. Match the THC strength to your own tolerance, not to the pharmacy's range. Start low, go slow.

So does THC not matter? No. It is the central dosing figure. Patients with low tolerance should deliberately start at a low percentage. But THC is one dimension among several; the type of effect depends on the whole profile.

Should I just buy by terpenes from now on? No, both count. THC sets the strength, terpenes set the character. A low-THC strain with the "wrong" terpene feels weak and off-target.

Are the THC values on pharmacy labels accurate in Germany? More reliable than on US dispensary stock (German pharmacy products are controlled under medicines law), but batch variation still happens. The certificate of analysis is the best reference.

Does high-potency cannabis make you more dependent? A separate question. There are signs of a link between high potency and higher rates of cannabis use disorder, but causality and confounding (who reaches for what?) are still open. For the question of acute effect, the Bidwell findings are solid.